SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Immix Biopharma, Inc. (IMMX) has a negative trailing P/E of -12.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 23.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -8.36%, forward earnings yield 4.31%. PEG 0.07 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (65/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.07); analyst target implies upside (+32%).
- Forward P/E 23.2 — analysts expect a return to profitability with estimated EPS of $0.43 for FY2029.
- PEG Ratio 0.07 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -8.36% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 4.31% as earnings recover.
- Analyst consensus target $13.00 (+32% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
65/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — IMMX
Valuation Multiples
P/E (TTM)-12.0
Forward P/E23.2
PEG Ratio0.07
Forward PEG0.07
P/B Ratio3.76
P/S Ratio0.00
EV/EBITDA-13.3
Per Share Data
EPS (TTM)$-0.77
Forward EPS (Est.)$0.43
Book Value / Share$2.45
Revenue / Share$0.00
FCF / Share$-0.64
Yields & Fair Value
Earnings Yield-8.36%
Forward Earnings Yield4.31%
Dividend Yield0.00%
Analyst Target$13.00 (+32%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-12.7 |
0.00 |
-3.40 |
0.00 |
- |
| 2020 |
-24.9 |
0.51 |
-6.03 |
0.00 |
- |
| 2021 |
-0.5 |
0.00 |
0.73 |
0.00 |
- |
| 2022 |
-3.9 |
0.04 |
2.42 |
0.00 |
- |
| 2023 |
-7.8 |
-0.15 |
7.31 |
0.00 |
- |
| 2024 |
-2.9 |
0.20 |
4.70 |
0.00 |
- |
| 2025 |
-5.9 |
-0.34 |
1.84 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.29 |
$0.00 |
$-972.81K |
- |
| 2020 |
$-0.15 |
$0.00 |
$-1.15M |
- |
| 2021 |
$-1.84 |
$0.00 |
$-24.38M |
- |
| 2022 |
$-0.62 |
$-89.52M |
$-8.23M |
- |
| 2023 |
$-0.89 |
$0.00 |
$-15.43M |
- |
| 2024 |
$-0.76 |
$0.00 |
$-21.61M |
- |
| 2025 |
$-0.89 |
$0.00 |
$-29.44M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.72 |
$-0.80 – $-0.68 |
$12.14M |
$8.58M – $15.59M |
4 |
| 2027 |
$-0.95 |
$-1.30 – $-0.59 |
$62.39M |
$44.09M – $80.1M |
2 |
| 2028 |
$-0.21 |
$-0.32 – $-0.10 |
$205.51M |
$205.51M – $205.51M |
2 |
| 2029 |
$0.43 |
$0.26 – $0.58 |
$332.06M |
$234.65M – $426.36M |
1 |
| 2030 |
$1.82 |
$1.13 – $2.49 |
$481.57M |
$340.31M – $618.34M |
1 |
